Astex Pharmaceuticals, Inc. (US)
Tom Davies has extensive experience in molecular sciences, with leadership roles at Astex Pharmaceuticals since December 2001. Prior to that, Tom worked as a Postdoctoral Research Associate in Structural Biology at the University of Oxford from November 1999 to December 2001. Tom also served as a Tutor in Biophysical Chemistry, teaching undergraduate Biochemists all aspects of physical chemistry. Tom holds a DPhil in Chemistry from the University of York, where Tom also obtained a BSc in Chemistry.
This person is not in any offices
Astex Pharmaceuticals, Inc. (US)
Astex Pharmaceuticals, Inc. (“Astex”) is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. Astex is a member of the Otsuka group of pharmaceutical companies. The group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex's products will be commercialized in the US and Canada by Taiho subsidiaries, and the rest of the world by Otsuka subsidiaries.